When cheap becomes fragile: How the race to the bottom in generics undermines manufacturing quality and what to do about it Pharmaceutical & Drug Policy When cheap becomes fragile: How the race to the bottom in generics undermines manufacturing quality and what to do about it Marta E. Wosińska March 24, 2026
Synthetic drug threats require a new international treaty Pharmaceutical & Drug Policy Synthetic drug threats require a new international treaty Richard J. Baum March 20, 2026
When medicine supply chains become weapons: China’s leverage and how the U.S. should respond Pharmaceutical & Drug Policy When medicine supply chains become weapons: China’s leverage and how the U.S. should respond Marta E. Wosińska March 19, 2026
Marta Wosińska’s testimony before the House Select Committee on the Chinese Communist Party Pharmaceutical & Drug Policy Marta Wosińska’s testimony before the House Select Committee on the Chinese Communist Party Marta E. Wosińska March 18, 2026